October 8, 2019

MPM’s Todd Foley Comments on Pharma Market in WSJ Pro VC “Pharma Mergers, Strong IPO Market Mute Startup Acquisitions”

In light of fewer acquisitions of VC backed biotechs in 2019, the value remains high, evidenced by Vertex $950M cash acquisition of MPM portfolio company Semma Therapeutics. Todd Foley comments that he isn’t seeing a risk-averse attitude among acquirers and companies with strong assets are getting lots of attention from potential buyers. (Full article available to WSJ Pro VC Subscribers only)